New drug indication approval - March 2024
For the most updated information related to registered therapeutic products, please refer to the Register of Therapeutic Products.
| Product Name | SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.83ML,
SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML,
SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML |
| Active Ingredient (Strength) | Risankizumab(75mg/0.83mL),
Risankizumab(150mg),
Risankizumab(150mg/mL) |
| Product Registrant | ABBVIE PTE. LTD. |
| Date of Approval | 26/03/2024 |
Indications:
SKYRIZI is indicated for the treatment of moderate to severe palmoplantar pustulosis in adults who do not adequately respond or are intolerant to conventional therapy. |
| Product Name | ERBITUX 5MG/ML |
| Active Ingredient (Strength) | Cetuximab, chimeric antibody(5mg/ml) |
| Product Registrant | MERCK PTE. LTD. |
| Date of Approval | 18/03/2024 |
Indications:
Erbitux is indicated in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy. |
Healthcare professional, Industry member, Therapeutic Products
Published:
New Drug Indication Approvals